Japan· JP-6132419F2018
セフトリアキソンナトリウム水和物
A ceftriaxone product containing セフトリアキソンナトリウム水和物, registered in Japan, on the national reimbursement list. The same ATC class is registered in 19 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Ceftriaxone is registered in 19 of 19 countries.
Countries holding a registration under ATC J01DD04 (ceftriaxone), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 11 of them publish a price we can compare per daily dose
Ceftriaxone · ATC J01DD04
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ceftriaxone costs, country by country.
Normalised to the WHO defined daily dose (2 g), the median price runs from $3.23 in Finland to $33.98 in Switzerland — a ×11 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceftriaxone · price per daily dose (2 g)
USD · FX 28 Sept 2026
- CH Switzerland$33.98
- FR France$13.68
- ES Spain$5.69
- FI Finland$3.23
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- セフトリアキソンナトリウム水和物
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- J01DD04
- ATC class
- Ceftriaxone
- Defined daily dose
- 2 g, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
233 interactions on record for ceftriaxone.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ceftriaxone · interactions on record
233 records
- 7 severe
- 20 moderate
- 3 minor
- 203 info
Most severe, free to view
- Calcium gluconateA12AA03severe
- Calcium chlorideA12AA07severe
- Calcium glucoheptonateA12AA10severe
- Calcium chlorideB05XA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01DD04
Ceftriaxone, as other registers publish it.
- PolandBiotraksonZakłady Farmaceutyczne POLPHARMA S.A.
- PolandBiotraksonZakłady Farmaceutyczne POLPHARMA S.A.
- ItalyBIXONLANOVA FARMACEUTICI S.R.L.
- ItalyCARITEXPHARMACARE S.R.L.
- FinlandCefonovaDr. Friedrich Eberth Arzneimittel GmbH
- FinlandCefonovaDr. Friedrich Eberth Arzneimittel GmbH
- ItalyCEFTAGESS.F. GROUP S.R.L.
- FinlandCeftriaxanneSandoz A/S
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd2f4f5f-3e31-46eb-8798-5c25acaf7947 GET /v1/drugs/cd2f4f5f-3e31-46eb-8798-5c25acaf7947?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｇ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6132419F2018",
"category": "注射薬",
"price_yen": null,
"generic_name": "セフトリアキソンナトリウム水和物",
"product_name_jp": null,
"therapeutic_class": "6132",
"transitional_expiry": null
}See everything about ceftriaxone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.